Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus TRIATEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus TRIATEX.
KERLEDEX vs TRIATEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
TRIATEX (methotrexate) inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby interfering with DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
Triatex (trianterene/hydrochlorothiazide) 37.5 mg/25 mg or 75 mg/50 mg orally once daily; may increase to maximum of 2 capsules daily.
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Terminal elimination half-life is 8-12 hours (mean 10 hours) in adults with normal renal function; prolonged to 20-40 hours in moderate-severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Primarily renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion) with 5-10% fecal elimination.
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid